Minami Yoshiro, Nagaoka Taiji, Ishibazawa Akihiro, Yoshida Akitoshi
Department of Ophthalmology, Nayoro City General Hospital, Nishi 7 Minami 8-1, Nayoro, 096-8511, Japan.
Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.
BMC Ophthalmol. 2017 Jun 13;17(1):90. doi: 10.1186/s12886-017-0485-4.
The correlation between the short- and long-term effects of intravitreal ranibizumab (IVR) on macular edema after branch retinal vein occlusion (BRVO) remains unclear. We assessed the correlation between the short- and long-term effects of IVR on macular edema after BRVO.
Twenty-one eyes with macular edema after BRVO were enrolled in this prospective observational study. We measured the foveal thickness (FT) and the best-corrected visual acuity (BCVA) before, 1 day after, and 1 month after IVR (0.5 mg) and then at least every 2 months thereafter until 6 months after the injection. If the macular edema recurred, another injection was administered. The primary endpoint was the change from baseline in the BCVA (ΔVA).
The mean logarithm of the minimum angle of resolution VA improved significantly (p = 0.01, p < 0.0001, respectively) after 1 day from 0.65 ± 0.28 to 0.51 ± 0.21 (20/89 to 20/63, Snellen equivalent) and after 6 months to 0.29 ± 0.24 (20/39, Snellen equivalent). The mean FT decreased significantly (p < 0.0001) after 1 day from 482 ± 85 μm to 349 ± 75 μm and after 6 months to 305 ± 84 μm. The 1-day VA was significantly (r = 0.68, p = 0.0007) positively correlated with the 6-month VA. The 1-day ΔVA was significantly (r = 0.79, p < 0.0001) positively correlated with the 6-month ΔVA.
The short-term effects of IVR may predict the long-term effects of IVR in macular edema secondary to BRVO.
Trial registration number: UMIN000027003 . Retrospectively registered. (April/15/2017).
玻璃体内注射雷珠单抗（IVR）对视网膜分支静脉阻塞（BRVO）后黄斑水肿的短期和长期影响之间的相关性尚不清楚。我们评估了IVR对BRVO后黄斑水肿的短期和长期影响之间的相关性。
本前瞻性观察性研究纳入了21只BRVO后出现黄斑水肿的眼睛。我们在IVR（0.5mg）注射前、注射后1天和1个月时测量了中心凹厚度（FT）和最佳矫正视力（BCVA），此后至少每2个月测量一次，直至注射后6个月。如果黄斑水肿复发，则再次注射。主要终点是BCVA相对于基线的变化（ΔVA）。
最小分辨角视力的平均对数在注射后1天从0.65±0.28显著提高到0.51±0.21（20/89至20/63，Snellen等效值）（p = 0.01，p < 0.0001），在6个月后提高到0.29±0.24（20/39，Snellen等效值）。平均FT在注射后1天从482±85μm显著降低到349±75μm（p < 0.0001），在6个月后降低到305±84μm。注射后1天的视力与6个月后的视力显著正相关（r = 0.68，p = 0.0007）。注射后1天的ΔVA与6个月后的ΔVA显著正相关（r = 0.79，p < 0.0001）。
IVR的短期效果可能预测其对BRVO继发黄斑水肿的长期效果。
试验注册号：UMIN000027003。回顾性注册。（2017年4月15日）
